Key result
Argatroban provides predictable direct thrombin inhibition for thrombosis prophylaxis and treatment in HIT.
Argatroban is a synthetic, small-molecule direct thrombin inhibitor that is approved in the USA, the EU and Japan for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia (HIT), and for anticoagulation of HIT patients undergoing PCI. Argatroban binds reversibly to, and inhibits both soluble and clot-bound thrombin. Argatroban does not generate antibodies, is not susceptible to degradation by proteases and is cleared hepatically. It has a predictable anticoagulant effect and there is a good correlation between dose, plasma concentration and pharmacodynamic effect. Initial clinical studies suggest that further investigations to establish the use of argatroban in ischemic stroke, acute coronary syndrome, hemodialysis, blood oxygenation, off-pump cardiac surgery and other clinical indications are warranted.
No takes yet. Share an insight, caveat, or question.
Jeske et al. (2010) conducted a review in Heparin-induced thrombocytopenia (HIT). Argatroban was evaluated. Argatroban is a synthetic direct thrombin inhibitor with a predictable anticoagulant effect that is approved for the prophylaxis or treatment of thrombosis in heparin-induced thrombocytopenia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: